The COVID-19 pandemic

M Ciotti, M Ciccozzi, A Terrinoni, WC Jiang… - Critical reviews in …, 2020 - Taylor & Francis
In December 2019, an outbreak of pneumonia of unknown origin was reported in Wuhan,
Hubei Province, China. Pneumonia cases were epidemiologically linked to the Huanan …

[HTML][HTML] Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications

IP Trougakos, K Stamatelopoulos, E Terpos… - Journal of Biomedical …, 2021 - Springer
Background Gaining further insights into SARS-CoV-2 routes of infection and the underlying
pathobiology of COVID-19 will support the design of rational treatments targeting the life …

TMPRSS2 expression dictates the entry route used by SARS‐CoV‐2 to infect host cells

J Koch, ZM Uckeley, P Doldan, M Stanifer… - The EMBO …, 2021 - embopress.org
SARS‐CoV‐2 is a newly emerged coronavirus that caused the global COVID‐19 outbreak in
early 2020. COVID‐19 is primarily associated with lung injury, but many other clinical …

[HTML][HTML] Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development

MM Zhao, WL Yang, FY Yang, L Zhang… - Signal transduction and …, 2021 - nature.com
To discover new drugs to combat COVID-19, an understanding of the molecular basis of
SARS-CoV-2 infection is urgently needed. Here, for the first time, we report the crucial role of …

Current status of plant metabolite-based fabrication of copper/copper oxide nanoparticles and their applications: a review

KS Siddiqi, A Husen - Biomaterials Research, 2020 - spj.science.org
Since green mode of nanoparticles (NPs) synthesis is simple, advantageous and
environment friendly relative to chemical and physical procedures, various plant species …

Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L

MD Sacco, C Ma, P Lagarias, A Gao, JA Townsend… - Science …, 2020 - science.org
The main protease (Mpro) of SARS-CoV-2 is a key antiviral drug target. While most Mpro
inhibitors have a γ-lactam glutamine surrogate at the P1 position, we recently found that …

[HTML][HTML] Multi-organ proteomic landscape of COVID-19 autopsies

X Nie, L Qian, R Sun, B Huang, X Dong, Q Xiao… - Cell, 2021 - cell.com
The molecular pathology of multi-organ injuries in COVID-19 patients remains unclear,
preventing effective therapeutics development. Here, we report a proteomic analysis of 144 …

[HTML][HTML] COVID-19 and cancer: current challenges and perspectives

Z Bakouny, JE Hawley, TK Choueiri, S Peters, BI Rini… - Cancer cell, 2020 - cell.com
Patients with cancer have been disproportionately affected by the COVID-19 pandemic. This
effect has included the adverse outcomes in patients with cancer who develop COVID-19 …

An updated review of computer‐aided drug design and its application to COVID‐19

AB Gurung, MA Ali, J Lee, MA Farah… - BioMed research …, 2021 - Wiley Online Library
The recent outbreak of the deadly coronavirus disease 19 (COVID‐19) pandemic poses
serious health concerns around the world. The lack of approved drugs or vaccines continues …

SARS-CoV-2 main protease drug design, assay development, and drug resistance studies

B Tan, R Joyce, H Tan, Y Hu… - Accounts of chemical …, 2022 - ACS Publications
Conspectus SARS-CoV-2 is the etiological pathogen of the COVID-19 pandemic, which led
to more than 6.5 million deaths since the beginning of the outbreak in December 2019. The …